Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136633

Published: 2020

Journal Articles

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

Antonio Sacco, RN, Cinzia Federico, PhD, Arianna Giacomini, PhD, Cinzia Caprio, PhD, Federica Maccarinelli, PhD, Katia Todoerti, PhD, Vanessa Favasuli, Antonella Anastasia, MD, Marina Motta, MD, Giuseppe Rossi, MD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Antonino Neri, MD, Roberto Ronca, PhD, Chiara Cattaneo, MD, Alessandra Tucci, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MDPhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136523

Published: 2020

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Cinzia Federico, PhD, Antonio Sacco, RN, Katia Todoerti, PhD, Arianna Giacomini, PhD, Gaia C Ghedini, PhD, Gaetana Lanzi, PhD, Marina Motta, MD, Antonella Anastasia, MD, Vanessa Favasuli, Roberto Ronca, PhD, Silvia Giliani, PhD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Giuseppe Rossi, Antonino Neri, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MD PhD

Blood (2019) 134 (Supplement_1): 1822.

https://doi.org/10.1182/blood-2019-126554

Published: 2019

Journal Articles

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, MD, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, Flavia Salvi, Antonella Anastasia, MD, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, MD, Anna Marina Liberati, MD, Nicola Di Renzo, MD, Luca Castagna, MD, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2018-99-118931

Published: 2018

Journal Articles

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Samantha Ferrari, MD, Alessandra Tucci, Gloria Valimberti, MD, Antonella Anastasia, MD, Chiara Bottelli, MD, Marta Petullà, Marina Motta, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2018) 132 (Supplement 1): 5328.

https://doi.org/10.1182/blood-2018-99-114896

Published: 2018

Journal Articles

Outcome of Transformed FL(t-FL) Worsens According to the Timing of Transformation and to the Number of Previous Therapies. A Survey of the Fondazione Italiana Linfomi (FIL)

Chiara Rusconi, MD, Antonella Anastasia, MD, Annalisa Chiarenza, Luigi Marcheselli, Federica Cavallo, Sara Rattotti, Barbara Botto, Angela Ferrari, Manuela Zanni, Marco Calabrese, Chiara Pagani, MD, Erika Meli, MD, Massimo Federico, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 3933.

https://doi.org/10.1182/blood.V126.23.3933.3933

Published: 2015

Journal Articles

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

Marina Motta, MD, Marco Chiarini, MSC, Marta Petullà, PharmD, Claudia Ghidini, BSC, Marion Vaglio Tessitore, BSC, Viviana Giustini, MSC, Chiara Pagani, MD, Antonella Anastasia, MD, Samantha Ferrari, MD, Alessandra Tucci, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 1531.

https://doi.org/10.1182/blood.V126.23.1531.1531

Published: 2015

Journal Articles

A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Marco Montillo, MD, Davide Rossi, Marina Motta, MD, Giulia Quaresmini, MD, Marianna Rossi, MD, Marta Coscia, MD, PhD, Antonella Anastasia, MD, Fausto Rossini, MD, Agostino Cortelezzi, MD, Guido Nador, MD, Lydia Scarfò, MD, Roberto Cairoli, MD, Daniela Dal Ceggio, MD, Lorenzo De Paoli, MD, Enrica Morra, MD, Alessandro Rambaldi, MD, Ester Orlandi, MD, Massimo Massaia, MD, Alessandra Tedeschi, MD

Blood (2013) 122 (21): 4177.

https://doi.org/10.1182/blood.V122.21.4177.4177

Published: 2013

Journal Articles

Mobilization of Hematopoietic Stem Cells by a Bendamustine-Containing Regimen in Hodgkin's Lymphoma

Antonella Anastasia, MD, Alessandro Pulsoni, Alessandro Re, MD, Francesco Merli, MD, Carmelo Carlo-Stella, MD, Cristina Gabutti, Luca Castagna, MD, Giorgia Annechini, Anna Marina Liberati, MD, Ercole Brusamolino, MD, Armando Santoro, MD

Blood (2012) 120 (21): 1914.

https://doi.org/10.1182/blood.V120.21.1914.1914

Published: 2012

Journal Articles

Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL)

Antonella Anastasia, MD, Carmelo Carlo-Stella, MD, Paolo Corradini, MD, Flavia Salvi, Chiara Rusconi, Alessandro Pulsoni, Stefan Hohaus, MD, Patrizia Pregno, Simonetta Viviani, MD, Ercole Brusamolino, MD, Stefano Luminari, Laura Giordano, MD, Armando Santoro, MD

Blood (2012) 120 (21): 3652.

https://doi.org/10.1182/blood.V120.21.3652.3652

Published: 2012

Journal Articles

Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy

Massimo Magagnoli, Katia Marzo, MD, Monica Balzarotti, Marcello Rodari, Rita Mazza, Laura Giordano, MD, Sara Gandolfi, MD, Stefania Bramanti, Antonella Anastasia, MD, Fabio Romano Lutman, MD, Arturo Chiti, MD, Armando Santoro

Blood (2011) 118 (21): 93.

https://doi.org/10.1182/blood.V118.21.93.93

Published: 2011

Journal Articles

Result of FDG PET Imaging After Chemotherapy +/− Immunotherapy Is a Significant and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: Survey From a Single Institution

Massimo Magagnoli, Rita Mazza, Sara Gandolfi, Marcello Rodari, Laura Giordano, MD, Antonella Anastasia, MD, Egesta Lopci, Arturo Chiti, Armando Santoro, Monica Balzarotti

Blood (2011) 118 (21): 2674.

https://doi.org/10.1182/blood.V118.21.2674.2674

Published: 2011

Journal Articles

Positron Emission Tomography Status and Tandem High-Dose Therapy Favorably Influence Outcome of Patients with Relapsed and/or Refractory Hodgkin Lymphoma

Raynier Devillier, MD, Diane Coso, MD, Luca Castagna, MD, Isabelle Brenot-Rossi, MD, Antonella Anastasia, MD, Arturo Chitit, MD, Jean Marc Schiano, MD, Armando Santoro, MD, Christian Chabannon, MD, PhD, Monica Balzarotti, MD, Didier Blaise, MD, Reda Bouabdallah, MD

Blood (2011) 118 (21): 335.

https://doi.org/10.1182/blood.V118.21.335.335

Published: 2011

Journal Articles

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV).

Antonella Anastasia, MD, Monica Balzarotti, Massimo Magagnoli, MD, Michele Spina, MD, Rita Mazza, MD, L. Castagna, Andrea Nozza, Stefania Bramanti, md, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro

Blood (2009) 114 (22): 1213.

https://doi.org/10.1182/blood.V114.22.1213.1213

Published: 2009

Journal Articles

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Rita Mazza, MD, Stefano Luminari, Massimo Magagnoli, MD, Michele Spina, MD, Teodoro Chisesi, MD, Antonio Pinto, MD, Massimo Federico, MD, Antonella Anastasia, MD, Arturo Chiti, MD, Mariagrazia Michieli, MD, Francesco Angrilli, MD, Luca Castagna, Giampaolo Marcacci, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro, Monica Balzarotti

Blood (2009) 114 (22): 3707.

https://doi.org/10.1182/blood.V114.22.3707.3707

Published: 2009

Journal Articles

Histological Parameters and “In Vitro” Cultures Identify Different Subsets of Myelofibrosis with Myeloid Metaplasia (MMM).

Federica Servida, PhD, Claudia Vener, MD, Viviana Tubazio, PhD, Umberto Gianelli, MD, Paola Rafaniello Raviele, PhD, Alessia Moro, PhD, Antonella Anastasia, MD, Giorgio Lambertenghi Deliliers, MD, Davide Soligo, MD, PhD

Blood (2005) 106 (11): 4952.

https://doi.org/10.1182/blood.V106.11.4952.4952

Published: 2005

NARROW

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Outcome of Transformed FL(t-FL) Worsens According to the Timing of Transformation and to the Number of Previous Therapies. A Survey of the Fondazione Italiana Linfomi (FIL)

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Mobilization of Hematopoietic Stem Cells by a Bendamustine-Containing Regimen in Hodgkin's Lymphoma

Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL)

Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy

Result of FDG PET Imaging After Chemotherapy +/− Immunotherapy Is a Significant and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: Survey From a Single Institution

Positron Emission Tomography Status and Tandem High-Dose Therapy Favorably Influence Outcome of Patients with Relapsed and/or Refractory Hodgkin Lymphoma

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV).

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Histological Parameters and “In Vitro” Cultures Identify Different Subsets of Myelofibrosis with Myeloid Metaplasia (MMM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only